Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


‘Disease Doesn’t Respect Silos’: Sharpless Sets Flexibility As Priority

Executive Summary

Acting US FDA Commissioner Ned Sharpless described his vision for an efficient, adaptable agency on 2 May at the Food & Drug Law Institute’s annual conference in Washington, DC.

You may also be interested in...

FDA Commissioner Hahn’s Priorities Include Workplace Development Issues, Data Collection

Among Stephen Hahn’s priorities and long-term ambitions for his time at the US agency are retaining and recruiting the best possible professional staff, and collection and use of data, regulatory consultants and attorneys say.

CMS Head Verma Unveils Favorable Coding Changes For Medtech, Pharma At MDMA Meeting

The US Centers for Medicare and Medicaid Services will allow device manufacturers to submit requests for HCPCS codes for emerging technology on a semi-annual basis, and drug-makers will be allowed to submit quarterly, CMS chief Seema Verma told an MDMA audience at the industry advocacy group's annual meeting on 2 May.

Unfinished Business: LDT Legislation A Top Priority For Departing FDA Chief Gottlieb

In a farewell talk at the Brookings Institution, outgoing US FDA Commissioner Scott Gottlieb said a top unfinished business that he hopes gets done after his April departure is legislation to regulate laboratory developed tests. While FDA had been looking to issue guidance on LDTs, he argues there isn’t sufficient legal authority for the agency to regulate the sector.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts